Longeveron Inc.
(NASDAQ : LGVN)

( )
LGVN After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -2.31%324.210.0%$4670.09m
BNTXBioNTech SE -1.06%247.680.0%$730.32m
NVAXNovavax, Inc. -4.59%161.9579.4%$715.24m
AMGNAmgen, Inc. 0.51%207.841.4%$575.65m
SNSSSunesis Pharmaceuticals, Inc. -7.57%6.470.7%$452.28m
GILDGilead Sciences, Inc. -0.76%67.631.0%$426.45m
REGNRegeneron Pharmaceuticals, Inc. -0.43%553.242.7%$408.99m
ILMNIllumina, Inc. 0.45%409.933.5%$392.87m
CCXIChemoCentryx, Inc. -7.04%34.472.9%$387.64m
XLRNAcceleron Pharma, Inc. 0.50%172.945.3%$345.45m
VRTXVertex Pharmaceuticals, Inc. -0.07%181.771.9%$259.59m
BIIBBiogen, Inc. -1.43%281.191.7%$243.39m
OCGNOcugen, Inc. -13.83%8.660.0%$178.37m
XENEXenon Pharmaceuticals, Inc. 2.12%33.660.4%$178.19m
JSPRJasper Therapeutics, Inc. 31.57%16.420.0%$158.53m

Company Profile

Longeveron LLC is a clinical stage biotechnology company that engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. The company was founded by Joshua M. Hare and Donald M. Soffers in October 9, 2014 and is headquartered in Miami, FL.